Agile Therapeutics announces delisting from Nasdaq

Agile Therapeutics announced that the company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550 requiring companies listed on Nasdaq to maintain stockholder’s equity of at least $2.5M. Suspension of trading in the company’s common stock on the Nasdaq exchange will be effective at the open of trading on March 26. Following the Nasdaq delisting, shares of the company’s common stock will continue to trade publicly. Effective March 26, the company’s common stock will be eligible for quotation and trading on the “over the counter” market operated by the OTC Markets. The company’s trading symbol will remain AGRX.